Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The real question is why the FDA is allowing an Adcom, when Elite was denied having one. There is more to Elite's tech we are not privy too yet. Not to be skeptical, but for sure raises eyebrows.
That makes complete sense. Thanks for your input. Forgot about the TPN issues & settlement several years ago.
Lol I was secretly hoping SunGen had a trick up their sleeves to catch everyone off guard.
Stop the conspiracy theory. Perhaps, just perhaps, there are real issues with the tech. We aren't yet privy to the deep details & analytics as of yet to know for sure.
Norco also falls under the label of a synthetic narcotic analgesic, but has a much bigger revenue potential. A few others I know of are buprenorphine, Demerol & methadone. Funny thing is I believe Fentanyl also falls into this category as a synthetic.
Great to see another ANDA, but not exactly the most impressive. Total revs of $40M split between how many equivalents? Not the greatest maneuver, but the pipeline continues to grow.
Is this first potential SunGen product?
We'll know in a few months how accurate that assumption is.
I have seen the same thing happen with stocks on NASDAQ. I believe Elite's tech will lead the company in a different direction.
As I just said I recently called. They tell 10Q or K data. This is what big companies do. They gave me both AS & OS as of the end of the reporting period.
If the TA was gagged they would not say anything. They would only refer you to the most recent financials. However, per John's point this is all they divulge. Elite's TA is at least providing the data from the most recent Q/K, but no more, which is what any management team that has a clue would set up.
I am ok with that. Elite won't be on OTC forever.
Give it a rest John. This is the standard.
That is exactly what any reputable big board company would do. They used to be on AMEX, have a plan to get to NASDAQ and are simply following standard norms. Nothing new here.
Thanks. Saved me 10 minutes from doing calc later tonight. We do know an 8k would have to be filed if the LPC agreement was extended/amended. Nothing forthcoming as of yet.
It is possible that they maxed out AS prior to LPC ending, but it is highly unlikely. No 8-K would be needed if they did max out to communicate to shareholders. We will know more in June.
Interesting to see it rise again. It dipped to 89% a couple of years ago and figured it was on a downwards slope.
Makes me wonder how others are making it to Adcom and Elite was rejected. Would have been good to hear dialogue and see much more analytics & details around Elite's tech.
Thx for sharing. Haven't dived too deep into Roxybond details yet.
All she did was confirm the authorized, not outstanding. They will only quote as of the last publicly filed statement, in this case the 10Q in Feb excluding subsequent event notes.
Yes, I call pure BS.
Absolutely full of it. TA doesn't give out that info. Posting as much garbage as many others here, but with the other slant.
The amount outstanding cannot exceed the amount authorized. Company charters often require a shareholder approval to increase share count, but not always. Same goes for reverse splits.
One option was to max out LPC entirely to buy company much needed time. Not entirely sure that didn't happen.
That is not what I asked. Send me a list of big board stocks that allow current day shares outstanding to be communicated to shareholders. I call BS, but am more than happy to be proven wrong.
He won't wait for it to max out before having a plan B. No CEO does this. You always want the available liquidity. But then again, this is his first time being CEO, but I am sure he will plan accordingly.
OTC or big board? If you are talking non-OTC stocks would love to see a list. I call BS...or clueless management.
Can you post it? It is not showing up on Reuters on my end. This was the 3rd forecast that went BUST!!
In working for public companies, in my experience not disseminating this information is the norm. When are you saying Elite stopped this? I still find it ridiculous for any public company that allows it. Makes zero sense.
Investors have no idea on those results. Let's not jump the gun. Results could be crap for all we know.
You are clearly assuming there are no further hiccups in the remaining timeline, something that has clearly not been the case over the last 3 years after many investors clamoring such garbage. In a time of political upheaval where large companies are gaining more favor I have a very hard time believing the timeline will be any faster than an FDA decision prior to June 2018. The company has already experienced delay after delay after delay. Timelines have been missed time and time again. With a sketchy ability to execute, an investor cannot assume that all of a sudden everything will be peachy keen and seamless overnight. Pure garbage.
I stand by June 2018. Any earlier is good news. Being too aggressive on earlier reviews has done absolutely no good. Time for some realism.
A threefold increase on nil is still nil. These revenue figures are laughable. Closer to CFP, but not there yet. Subsequent events said 6.6M dilution during 6 week period since end of quarter. If NOL's weren't sold dilution would have been even more. Dilution will be happening for several more months unless we get a real partnership with cash upfront. SequestOx deal will bring in $ if approved, but we are at least 15 months away from that.
To be fair 527M + 11M (subsequent events) = 538M from Feb '14 filing.
Feb '16 filing = 918M + 6.6M = ~925M in subsequent events. Using these both apples to apples latest info at time of filing is closer to 72% increase in dilution.
For this kind of dilution, this tech better be worth it. FDA validation of ER & IR will be a game changer. Still lots of uncertainty. Never know what other stops FDA will pull.
LOL Let me help you with you with that math. The independent valuation was communicated in Feb '14. At that point there were 527M shares outstanding.
925M OS today per latest Q and 527M (per Feb '14 10-Q).
(925M - 527M) / 527M = 75.5% increase in share count.
Don't forget that dilution has caused an increase of 75% outstanding share count. Revenue is still paltry at best. Until the tech receives FDA approval future, revenues of much grander proportions are erroneous options to even consider.
The grand majority do not disclose this. Because a rare group choose to do so does not make it the norm.
My shot was at all the ridiculous commentary that Elite will own 100% every market. Pure rubbish time and time again.
Oh yeah, there are currently drugs being sold in those markets that Elite dreams of entering. Not today, not tomorrow, but perhaps one day they will get a tiny sliver. Need to get real for a change.
You do realize that is normal, right? Larger companies do the exact same. On rare occasion for consulting engagements the firm is communicated. I have never heard of a company divulging the company providing a valuation. Never.
PPS may or may not take a hit, but like no-term sales potential will. Available slice of pie will significantly shrink.
Umm, yes it will. What happened to hammerlock on the IR market? Whoopsy.